Chirocaine ketorolac epinephrine — Competitive Intelligence Brief

Chirocaine ketorolac epinephrine (Chirocaine ketorolac epinephrine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination with NSAID and vasopressor. Area: Pain Management, Surgery, Anesthesia.

phase 3 Local anesthetic combination with NSAID and vasopressor Voltage-gated sodium channels (chirocaine); COX-1/COX-2 (ketorolac); alpha-1 and beta-adrenergic receptors (epinephrine) Pain Management, Surgery, Anesthesia Small molecule

Target snapshot

Chirocaine ketorolac epinephrine (Chirocaine ketorolac epinephrine) — maximiliano barahona vasquez. This combination drug provides local anesthesia via chirocaine, reduces inflammation and pain via ketorolac, and enhances vasoconstriction and hemostasis via epinephrine.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chirocaine ketorolac epinephrine TARGET	Chirocaine ketorolac epinephrine	maximiliano barahona vasquez	phase 3	Local anesthetic combination with NSAID and vasopressor	Voltage-gated sodium channels (chirocaine); COX-1/COX-2 (ketorolac); alpha-1 and beta-adrenergic receptors (epinephrine)
Ropivacaine, Ketorolac and Adrenaline	Ropivacaine, Ketorolac and Adrenaline	University of Aarhus	marketed	Local anesthetic combination with NSAID and vasopressor	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination with NSAID and vasopressor class)

1. University of Aarhus · 1 drug in this class
2. maximiliano barahona vasquez · 1 drug in this class